Search

Search

Home
...
Research Domains Biomedical and Clinical Sciences Oncology and Carcinogenesis Predictive and prognostic markers
Research Domains
Biomedical and Clinical Sciences
Oncology and Carcinogenesis
Predictive and prognostic markers
[Amivantamab with lazertinib - stage IV non-small cell lung cancer with EGFR exon 19 deletion or L858R mutation]

[Amivantamab with lazertinib - stage IV non-small cell lung cancer with EGFR exon 19 deletion or L858R mutation]

Marie Adou ¹, Florian Guisier ²

Marie Adou ¹, Florian Guisier ²

¹UFR de médecine, université Paris Cité, 75005 Paris, France.
²Service de Pneumologie, CHU de Rouen, 76000 Rouen, France.

⁰UFR de médecine, université Paris Cité, 75005 Paris, France.

Bulletin Du Cancer +

|

May 16, 2025

|

May 16, 2025

Related Experiment Videos

Contact us if these videos are not relevant.

Summary

No abstract available on PubMed

Keywords:

Amivantamab Carcinome bronchique non à petites cellules EGFR Lazertinib Non-small cell lung cancer Osimertinib

Related Experiment Videos

Contact us if these videos are not relevant.

Related Concept Videos

Share

X
Facebook
LinkedIn
YouTube

ABOUT JoVE

Overview
Leadership
Blog
JoVE Help Center

AUTHORS

Publishing Process
Editorial Board
Scope & Policies
Peer Review
FAQ
Submit

LIBRARIANS

Testimonials
Subscriptions
Access
Resources
Library Advisory Board
FAQ

RESEARCH

JoVE Journal
Methods Collections
JoVE Encyclopedia of Experiments
Archive

EDUCATION

JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Faculty Resource Center
Faculty Site

Terms & Conditions of Use
Privacy Policy
Policies